Risedronate Enters Into Phase 3 Clinical Programs In Japan

Risedronate sodium hydrate is a bisphosphonate antiosteoporotic agent, which is currently approved in more than 90 countries. A once-monthly formulation of risedronate sodium hydrate was already approved outside of Japan so that patients can have additional options for administration.

In Japan, a once-daily formulation of risedronate sodium hydrate was launched in May 2002 and a once-weekly formulation was launched in June 2007 for the treatment of osteoporosis. In Japan, risedronate sodium hydrate is being marketed under the brand names Actonel by Eisai (Eisai) and Benet by Takeda respectively.

The once-monthly formulation is expected to enhance the convenience of administration for patients compared to a once-daily or a once-weekly formulation. A variety of formulations will provide a range of choices for patients and enable to receive the formulation that best suits their lifestyle.